Key Points
- Vaxcyte EVP Jim Wassil sold 2,250 shares at an average price of $56.67, generating $127,507.50. The sale was conducted under a pre-arranged Rule 10b5-1 plan, leaving him with 145,435 shares.
- Vaxcyte shares opened at $56.48, with an $8.40 billion market capitalization and a 52-week range of $39.87 to $65.00. The company reported a quarterly loss of $1.97 per share, beating the $2.06 consensus estimate.
- Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $104.40. Institutional investors own 96.78% of the stock.
Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) EVP Jim Wassil sold 2,250 shares of the business's stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $56.67, for a total transaction of $127,507.50. Following the completion of the sale, the executive vice president owned 145,435 shares of the company's stock, valued at approximately $8,241,801.45. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jim Wassil also recently made the following trade(s):
- On Wednesday, September 9th, Jim Wassil sold 1,334 shares of Vaxcyte stock. The stock was sold at an average price of $59.52, for a total transaction of $79,399.68.
- On Friday, September 4th, Jim Wassil sold 1,381 shares of Vaxcyte stock. The stock was sold at an average price of $61.16, for a total transaction of $84,461.96.
- On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The shares were sold at an average price of $61.07, for a total transaction of $212,340.39.
- On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $53.86, for a total transaction of $121,185.00.
Vaxcyte Stock Up 0.8%
Shares of NASDAQ PCVX opened at $56.48 on Friday. The stock has a market capitalization of $8.40 billion, a PE ratio of -7.40 and a beta of 1.23. The firm has a fifty day moving average of $58.67 and a 200-day moving average of $56.18. Vaxcyte, Inc. has a 52-week low of $39.87 and a 52-week high of $65.00.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.06) by $0.09. During the same period in the previous year, the business earned ($1.22) earnings per share. Equities research analysts expect that Vaxcyte, Inc. will post -7.6 EPS for the current fiscal year.
Institutional Trading of Vaxcyte
Large investors have recently added to or reduced their stakes in the stock. Jupiter Topco LLC purchased a new position in Vaxcyte in the second quarter valued at about $1,044,355,000. Janus Henderson Group PLC lifted its stake in shares of Vaxcyte by 23.8% during the first quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company's stock worth $960,231,000 after purchasing an additional 3,188,687 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Vaxcyte in the second quarter worth about $701,520,000. T. Rowe Price Investment Management Inc. boosted its position in shares of Vaxcyte by 35.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 11,296,333 shares of the company's stock worth $521,213,000 after buying an additional 2,981,038 shares during the period. Finally, Wellington Management Group LLP grew its stake in shares of Vaxcyte by 24.7% in the second quarter. Wellington Management Group LLP now owns 7,001,565 shares of the company's stock valued at $407,001,000 after buying an additional 1,386,968 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several equities research analysts have commented on the company. Zacks Research upgraded Vaxcyte from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 12th. Needham & Company LLC reiterated a "buy" rating and set a $110.00 target price on shares of Vaxcyte in a report on Friday, September 25th. Bank of America decreased their target price on Vaxcyte from $133.00 to $130.00 and set a "buy" rating for the company in a report on Monday. Wall Street Zen upgraded shares of Vaxcyte from a "strong sell" rating to a "sell" rating in a report on Saturday, August 8th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Vaxcyte in a report on Monday, July 6th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $104.40.
Read Our Latest Analysis on Vaxcyte
About Vaxcyte
(
Get Free Report)
Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines to help prevent serious bacterial infections. The company uses its cell-free protein synthesis and advanced conjugation technologies to design vaccines intended to provide broad and durable protection while addressing limitations of existing vaccine products.
Vaxcyte's lead programs are pneumococcal conjugate vaccine candidates, including VAX-24 and VAX-31, which are designed to target a broad range of pneumococcal serotypes.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
